TechAnalyzer ProBrainsway Ltd BWAY
Stock research in plain language · As of Oct 12, 2026 · updated once a week, after the trading week closes
Daily candles, 50 and 200-day averages and volume · updated every trading day · click to open the live chart
What the company does
Brainsway Ltd is a small-cap company in the Healthcare sector (Medical Devices), with a market value of $474M, based in the USA.
It employs about 129 people and has been listed since Oct 06, 1999.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Cheap or expensive? relatively expensive
Its price-to-earnings (P/E) is 51.2 versus 32.8 for the median of the Healthcare sector in our universe (25 companies) — relatively expensive.
Revenue is growing 35% a year — the market is paying ahead for that growth. If it slows, the high multiple becomes the risk.
On analysts' next-year forecasts the multiple drops to 17.9 — they expect higher earnings.
The average analyst price target is 19.27, 64% above the current price (their view, not ours).
The stock sits at 45% of its one-year range (0% = the low, 100% = the high).
The risks
- • The stock is more volatile than average (beta 0.1) — big daily moves both ways.
- • The stock is 32% below its one-year high.
- • Low trading volume — hard to buy or sell size without moving the price.
Strengths
- ✅ Profitable — 16 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Buys back its shares (47% fewer shares in a year).
- ✅ More cash than debt.
- ✅ Revenue is growing 35% a year.
What changed this week
Over the past week the stock fell 5.8% (for comparison: S&P 500 +1.2%, sector ETF XLV +2.8%).
No notable news about the company was found in the past week.
What changed since last week
This is the first summary for this stock; from next week this section shows what changed.
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.